- Home
- RARE vs OGN Comparison
RARE vs OGN Comparison
Compare RARE & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | OGN |
|---|---|---|
| Founded | 2010 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.7B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | RARE | OGN |
|---|---|---|
| Price | $33.60 | $7.43 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 4 |
| Target Price | ★ $85.20 | $15.75 |
| AVG Volume (30 Days) | 1.4M | ★ 6.4M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | ★ 1.04% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.91 |
| Revenue | $630,598,000.00 | ★ $6,301,000,000.00 |
| Revenue This Year | $19.65 | N/A |
| Revenue Next Year | $23.65 | $0.65 |
| P/E Ratio | ★ N/A | $4.03 |
| Revenue Growth | ★ 20.63 | N/A |
| 52 Week Low | $25.81 | $6.18 |
| 52 Week High | $50.00 | $17.23 |
Technical Indicators
Market Signals| Indicator | RARE | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 44.29 |
| Support Level | $32.06 | $6.95 |
| Resistance Level | $34.77 | $7.86 |
| Average True Range (ATR) | 1.40 | 0.35 |
| MACD | 0.08 | 0.11 |
| Stochastic Oscillator | 66.67 | 44.39 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.